Universal Technical Institute Inc is an educational institution... Show more
Universal Technical Institute (NYSE: UTI) is a mid-cap education provider with a market capitalization of approximately $1.0 billion and roughly 55.1 million shares outstanding. The shares have traded in a broad range over the past year, climbing to a 52-week high of $51.34 in early July 2026 before retreating to a 52-week low of $18.46 in late September 2026. The stock has since stabilized near the $20 level and pays a modest annualized dividend of $0.16 per share.
The broader career-education sector has faced mixed sentiment as investors weigh strong enrollment demand against margin pressure and execution challenges. Within that context, UTI's valuation reflects both its expansion potential and questions about near-term profitability, with a trailing price-to-earnings ratio near 30 based on the company's last twelve months of results.
Founded in 1965 and headquartered in Phoenix, Arizona, Universal Technical Institute is a workforce-solutions provider that prepares students for in-demand careers through two operating divisions. The UTI division operates 16 campuses across nine states and offers programs in automotive, diesel, collision repair, motorcycle, marine, welding, computer numerical control (CNC) machining, electrical, and energy technologies. The Concorde Career Colleges division operates 18 campuses across eight states plus online programs, focusing on allied health, dental, nursing, patient care, and diagnostic fields.
UTI competes in a fragmented market alongside other publicly traded education providers such as Lincoln Educational Services (LINC) and healthcare-focused peers like Adtalem Global Education (ATGE). The company's "North Star" growth strategy emphasizes new campus openings, manufacturer-aligned training partnerships, and expansion of its healthcare footprint. A central competitive advantage is persistent employer demand: management has noted that job openings for automotive and diesel technicians far exceed the number of graduates the company produces, supporting long-term enrollment demand.
The most significant recent catalyst was the company's fiscal 2026 third-quarter report for the period ended June 30, 2026. Revenue increased 7.2% year over year to $218.9 million, driven by enrollment growth across both divisions. Concorde revenue rose 11.1% to $80.9 million, while UTI division revenue increased 5% to $138 million. Average full-time active students grew 5.8% to 25,131, and new student starts climbed 10.9% to 6,342.
Profitability, however, remained under pressure. Net income declined to $2.3 million, or $0.04 per diluted share, compared with $10.7 million, or $0.20 per share, in the prior-year quarter. Management also lowered its fiscal 2026 outlook, citing two factors: a softer-than-expected fourth-quarter high-school starts outlook in the UTI division's automotive and diesel programs, and a faster-than-anticipated shift toward shorter-duration skilled-trades programs that generate less revenue per student.
Notably, leadership characterized the high-school shortfall as an execution issue rather than a demand problem, attributing it to insufficient admissions staffing and indicating that field representatives had been expanded by roughly 20%. These dynamics have tempered investor sentiment even as the company's underlying enrollment growth remains intact.
Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading bots drawn from a broader universe of hundreds of AI-driven strategies that monitor thousands of tickers. Because only the top-performing and most relevant bots are surfaced in this section, traders can quickly scan for strategies that are currently demonstrating strength. The bots featured vary widely in approach, holding timeframe, and performance metrics, allowing users to evaluate options aligned with different risk tolerances and trading styles. For investors tracking education and workforce-training names, exploring these automated tools can offer an additional, data-driven lens on market activity.
Looking ahead, investors are likely to focus on several forward-looking drivers. The company's fiscal fourth-quarter and full-year results, which wrap up the fiscal year ending September 30, 2026, will clarify whether the high-school channel rebound and improved admissions staffing translate into stronger starts. The initial guidance for fiscal 2027 will also be closely watched for signals on revenue growth, margin trajectory, and the pace of growth-related investment spending.
Operational themes remain central: the mix between longer automotive and diesel programs and shorter skilled-trades offerings, the ramp of new campuses, and continued demand in Concorde's healthcare programs. Broader factors such as interest rates, student financing conditions, and the regulatory environment for postsecondary education could also influence enrollment and sentiment. These are factual considerations for investors to monitor rather than predictive signals of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
UTI moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 38 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UTI as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The 10-day moving average for UTI crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +1.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in 258 of 329 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 188 of 250 cases where UTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The 10-day RSI Indicator for UTI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 28 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 69 cases where UTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
UTI broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. UTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: UTI's P/B Ratio (3.472) is slightly higher than the industry average of (1.260). UTI has a moderately high P/E Ratio (35.000) as compared to the industry average of (9.322). Projected Growth (PEG Ratio) (1.642) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (3.423) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (27.566).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of technical education
Industry OtherConsumerSpecialties